Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2017 16:30 ET | Source: Argos Therapeutics, Inc.

Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.

DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
November 06, 2017 10:04 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017

DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
September 26, 2017 16:30 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors

DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
September 19, 2017 08:30 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
September 12, 2017 08:00 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress

DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
September 06, 2017 08:00 ET | Source: Argos Therapeutics Inc.

Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir

DURHAM, N.C., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
August 21, 2017 08:30 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress

DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
August 09, 2017 17:04 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights

- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data...
July 26, 2017 08:00 ET | Source: Argos Therapeutics Inc.

Argos Reports Immunogenicity Results of AGS-004 in HIV Program

DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...
June 22, 2017 08:00 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing

DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies...